Showing 1672 results
-
Story /Accelerating Research to Get Answers Faster
-
Press release /First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
-
Press release /Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] …
-
Press release /New findings show Cosentyx® (secukinumab) 300 mg single dose autoinjector (the UnoReady® pen) resulted in superior efficacy vs placebo1 Patient satisfaction with 300 mg autoinjector…
-
Press release /SEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-…
-
Press release /26 potential blockbusters in confirmatory development[1]. 13 projects in clinical development across Cell, Gene & Radioligand therapies. 60 major submissions[2] planned from 2019 to 2021…
-
Story /Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.
-
Press release /2016 marks 30 years of commitment by the Novartis Foundation to support people affected by leprosy and to end this ancient disease New strategy from the Novartis Foundation to accelerate…
-
Press release /Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…